Artesunate Ameliorates Functional Limitations in Freund’s Complete Adjuvant-Induced Monoarthritis in Rat by Maintaining Oxidative Homeostasis and Inhibiting COX-2 Expression

Inflammation

Volumn 38, Issue 3, 2015, Pages 1028-1035

  Guruprasad, B ^a   Chaudhary, Priyanka ^a   Choedon, Tenzin ^b   Kumar, Vijay L ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

artesunate; arthritis; COX 2 expression; inflammatory hyperalgesia; oxidative homeostasis

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; CYCLOOXYGENASE 2; DICLOFENAC; FREUND ADJUVANT; NITRIC OXIDE; PLANT EXTRACT; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, RAT;

ANIMAL; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HYPERALGESIA; IMMUNOLOGY; INFLAMMATION; JOINT; MALE; METABOLISM; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; OXIDATIVE STRESS; PATHOLOGY; RAT; WISTAR RAT;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; ARTEMISININS; ARTHRITIS, EXPERIMENTAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; FEMALE; FREUND'S ADJUVANT; HYPERALGESIA; INFLAMMATION; JOINTS; MALE; NEUTROPHIL INFILTRATION; NEUTROPHILS; NITRIC OXIDE; OXIDATIVE STRESS; PLANT EXTRACTS; RATS; RATS, WISTAR;

EID: 84939955743     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0067-z     Document Type: Article

References (43)

1. Gabriel, S.E. 2010. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 69: i61–i64.
2. Wong, J.B., D.R. Ramey, and G. Singh. 2001. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 44: 2746–2749.
3. Kunkel, S.L., N. Lukacs, T. Kasama, and R.M. Strieter. 1996. The role of chemokines in inflammatory joint disease. J Leukoc Biol 59: 6–12.
4. Hootman, J.M., and C.G. Helmick. 2006. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 54: 226–229.
5. Crofford, L.J. 2013. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 15: S2.
6. Vane, J.R., and R.M. Botting. 1997. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 26: 2–10.
7. Salliot, C., A. Finckh, W. Katchamart, Y. Lu, Y. Sun, C. Bombardier, and E. Keystone. 2011. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70: 266–271.
8. Watson, D.J., J.A. Bolognese, C. Yu, D. Krupa, and S. Curtis. 2004. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 20: 1899–1908.
9. Graziose, R., M.A. Lila, and I. Raskin. 2010. Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional food. Curr Drug Discov Technol 7: 2–12.
10. Jin, O., H. Zhang, Z. Gu, S. Zhao, T. Xu, K. Zhou, B. Jiang, J. Wang, X. Zeng, and L. Sun. 2009. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol 6: 461–467.
11. Li, B., R. Zhang, J. Li, L. Zhang, G. Ding, P. Luo, S. He, Y. Dong, W. Jiang, Y. Lu, H. Cao, J. Zhang, and H. Zhou. 2008. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation. Int Immunopharmacol 8: 379–389.
12. Li, B., J. Li, X. Pan, G. Ding, H. Cao, W. Jiang, J. Zheng, and H. Zhou. 2010. Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF- alpha release via inhibition of TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation. Int Immunopharmacol 10: 344–350.
13. He, Y., J. Fan, H. Lin, X. Yang, Y. Ye, L. Liang, Z. Zhan, X. Dong, L. Sun, and H. Xu. 2011. The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1α in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int 31: 53–60.
14. Li, Y., S. Wang, Y. Wang, C. Zhou, G. Chen, W. Shen, C. Li, W. Lin, S. Lin, H. Huang, P. Liu, and X. Shen. 2013. Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Transl Res 161: 89–98.
15. Kumar, V.L., B. Guruprasad, and P. Chaudhary. 2014. Antimalarial drug artesunate affords protection against carrageenan induced acute inflammation in rat. Biocell (in press).
16. Lam, F.F., and E.S. Ng. 2010. Substance P and glutamate receptor antagonists improve the anti-arthritic actions of dexamethasone in rats. Br J Pharmacol 159: 958–969.
17. Kumar, V.L., P. Chaudhary, R.M. Oliveira, and M.V. Ramos. 2014. Calotropis procera latex proteins ameliorate functional limitations associated with adjuvant induced inflammation in rat. Musculoskelet Biol 1: 1.
18. De Castro Costa, M., P. De Sutter, J. Gybels, and J. Van Hees. 1981. Adjuvant-induced arthritis in rats: a possible animal model of chronic pain. Pain 10: 173–185.
19. Butler, S.H., F. Godefroy, J.M. Besson, and J. Weil-Fugazza. 1992. A limited arthritic model for chronic pain studies in the rat. Pain 48: 73–81.
20. Wahane, V.D., and V.L. Kumar. 2010. Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. Pharmacol Res 61: 329–333.
21. Wang, Y., C. Huang, Y. Cao, and J.S. Han. 2000. Repeated administration of low dose ketamine for the treatment of monoarthritic pain in the rat. Life Sci 67: 261–267.
22. Bradley, P.P., D.A. Preibat, R.D. Christensen, and G. Rothstein. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206–209.
23. Feng, Q., X. Lu, D.L. Jones, J. Shen, and J.M. Arnold. 2001. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104: 700–704.
24. Ellman, G.L. 1959. Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70–77.
25. Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351–358.
26. Lin, N., C. Liu, C. Xiao, H. Jia, K. Imada, H. Wu, and A. Ito. 2007. Triptolide, diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis mice. Biochem Pharmacol 73: 136–146.
27. de Grauw, J.C., C.H.A. van de Lest, and P.R. van Weeren. 2009. Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study. Arthritis Res Ther 11: R35.
28. Kroon, J., S. Tol, S. van Amstel, J.A. Elias, and M. Fernandez- Borja. 2013. The small GTPase RhoB regulates TNFα signaling in endothelial cells. PLoS One 8: e75031.
29. Leung, L., and C.M. Cahill. 2010. TNF-alpha and neuropathic pain-a review. J Neuroinflammation 7: 27.
30. Nakao, S., Y. Ogtata, E. Shimizu, M. Yamazaki, S. Furuyama, and H. Sugiya. 2002. Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. Mol Cell Biochem 238: 11–18.
31. Dubois, R.N., S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, L.B. Van De Putte, and P.E. Lipsky. 1998. Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073.
32. Telleria-Diaz, A., M. Schmidt, S. Kreusch, A.K. Neubert, F. Schache, E. Vazquez, H. Vanegas, H.G. Schaible, and A. Ebersberger. 2010. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain 148: 26–35.
33. Ben-Baruch, A., D.F. Michiel, and J.J. Oppenheim. 1995. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 270: 11703–11706.
34. Lemos, H.P., R. Grespan, S.M. Vieira, T.M. Cunha, W.A. Verri Jr., K.S. Fernandes, F.O. Souto, I.B. McInnes, S.H. Ferreira, F.Y. Liew, and F.Q. Cunha. 2009. Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc Natl Acad Sci U S A 106: 5954–5959.
35. Ziskoven, C., M. Jäger, J. Kircher, T. Patzer, W. Bloch, K. Brixius, and R. Krauspe. 2011. Physiology and pathophysiology of nitrosative and oxidative stress in osteoarthritic joint destruction. Can J Physiol Pharmacol 89: 455–466.
36. Hitchon, C.A., and H.S. El-Gabalawy. 2004. Oxidation in rheumatoid arthritis. Arthritis Res Ther 6: 265–278.
37. Kannan, K., and S.K. Jain. 2000. Oxidative stress and apoptosis. Pathophysiology 7: 153–163.
38. Moncada, S., and A. Higgs. 1993. The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002–2012.
39. Salvemini, D., S.L. Settle, J.L. Masferrer, K. Seibert, M.G. Currie, and P. Needleman. 1995. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol 114: 1171–1178.
40. Ersoy, Y., E. Ozerol, O. Baysal, I. Temel, R.S. MacWalter, U. Meral, and Z.E. Altay. 2002. Serum nitrate and nitrite levels in patients with rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. Ann Rheum Dis 61: 76–78.
41. Yang, Y.H., P. Hutchinson, L.L. Santos, and E.F. Morand. 1998. Glucocorticoid inhibition of adjuvant arthritis synovial macrophage nitric oxide production: role of lipocortin 1. Clin Exp Immunol 111: 117–122.
42. Wright, H.L., R.J. Moots, R.C. Bucknall, and S.W. Edwards. 2010. Neutrophil function in inflammation and inflammatory diseases. Rheumatology 49: 1618–1631.
43. Adán, N., J. Guzmán-Morales, M.G. Ledesma-Colunga, S.I. Perales-Canales, A. Quintanar-Stéphano, F. López-Barrera, I. Mendez, B. Moreno-Carranza, J. Triebel, N. Binart, G. Martinez de la Escalera, S. Thebault, and C. Clapp. 2013. Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. J Clin Invest 123: 3902–3913.